Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience

REFERENCES

1. 1.↵
   1. Papp K,
   2. Reich K,
   3. Leonardi CL, et al

   . Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM1]). J Am Acad Dermatol 2015;73:37-49.

   OpenUrlCrossRefPubMed
2. 2.
   1. Paul C,
   2. Cather J,
   3. Gooderham M, et al

   . Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol 2015;173:1387-99.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Schett G,
   2. Wollenhaupt J,
   3. Papp K, et al

   . Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156-67.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Kavanaugh A,
   2. Mease PJ,
   3. Gomez-Reino JJ, et al

   . Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020-6.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Edwards CJ,
   2. Blanco FJ,
   3. Crowley J, et al

   . Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016;75:1065-73.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Favalli EG,
   2. Conti F,
   3. Selmi C, et al

   . Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. Clin Exp Rheumatol 2020;381:19-26.

   OpenUrl
7. 7.↵
   1. Taylor W,
   2. Gladman D,
   3. Helliwell P,
   4. Marchesoni A,
   5. Mease P,
   6. Mielants H; CASPAR Study Group

   . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.

   OpenUrlCrossRefPubMed